During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
In the first segment of Nine for 2024, we examined the continued fragility of healthcare systems, global pharmaceutical market infrastructure, and the journey to greater resilience.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh